Expertise in
13
conditions

Dr. Mark Roschewski

Hematology
Office
7707 Wisconsin Ave Apt 1106, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 5 Trials
Expertise in
13
conditions
Office
7707 Wisconsin Ave Apt 1106, 
Bethesda, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Roschewski is a Hematologist in Bethesda, Maryland. Dr. Roschewski is highly rated in 13 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Smoldering Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), and Vitrectomy.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in AK
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
7707 Wisconsin Ave Apt 1106, Bethesda, MD 20814

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Enrollment Status: Recruiting
Publish Date: January 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib
Study Phase: Phase 1
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Enrollment Status: Recruiting
Publish Date: January 16, 2026
Intervention Type: Biological
Study Drug: Nivolumab
Study Phase: Phase 2
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Enrollment Status: Recruiting
Publish Date: January 09, 2026
A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma
A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma
Enrollment Status: Recruiting
Publish Date: January 08, 2026
Intervention Type: Biological, Drug
Study Drugs: DA-EPOCH, Rituximab, CHOP, Acalabrutinib
Study Phase: Phase 2
Prospective Study of Clonal Evolution in Follicular Lymphoma
Prospective Study of Clonal Evolution in Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: December 18, 2025
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug, Biological
Study Drugs: Dexamethasone, Carfilzomib, Daratumumab
Study Phase: Phase 2
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Diagnostic test, Drug, Combination product, Other
Study Drugs: Obinutuzumab, Nivolumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib
Study Phase: Phase 1
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, filgrastim, EPOCH
Study Phase: Phase 2
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drugs: TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole
Study Phase: Phase 2
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Study Phase: Phase 1
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Biological, Diagnostic test, Drug, Procedure
Study Drugs: IFN-Alpha, Rituximab, EPOCH
Study Phase: Phase 2
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Rituximab, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma: a Clinical and Correlative Pilot Study
Enrollment Status: Completed
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Revlimid, Dexamethasone
Study Phase: Phase 2
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Clinical and Correlative Phase II Study
Enrollment Status: Completed
Publish Date: March 02, 2021
Intervention Type: Drug
Study Phase: Phase 2
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
Enrollment Status: Terminated
Publish Date: February 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

124 Total Publications

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (4.1 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Hormone Replacement Therapy (HRT), and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (11.4 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her top areas of expertise are Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
22
conditions
Dr. Craig Kessler
Hematology
Expertise in
22
conditions
Dr. Craig Kessler
Hematology

MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (5.1 miles away)
202-444-2223
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Craig Kessler is a Hematologist in Washington, Washington, D.c.. Dr. Kessler is highly rated in 22 conditions, according to our data. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roschewski's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile